<DOC>
	<DOC>NCT01528826</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy and safety of vinorelbine plus oxaliplatin in pretreated metastatic triple-negative breast cancer.</brief_summary>
	<brief_title>Salvage Chemotherapy of Vinorelbine Plus Oxaliplatin in Metastatic Triple-negative Breast Cancer:a Prospective Trial</brief_title>
	<detailed_description>Triple-negative breast cancer is associated with less treatment choices and shorter overall survival. Both vinorebine and oxaliplatin are effective in metastatic breast cancer. The investigators designed this trial to evaluate the combination of these two drugs in pretreated metastatic triple-negative breast cancer.</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>1. Females with age between 18 and 70 years old 2. ECOG performance between 02 3. Life expectancy more than 3 months 4. Histological proven unresectable recurrent or advanced breast cancer 5. Triplenegative for estrogen receptor (ER), progestogen receptor (PR), and human epithelial receptor2 (HER2) by immunohistochemistry (IHC) test. For patients with ER negative, PR negative, Her2 two plus, a negative Her2 gene amplification should be verified with FISH test. Her2 one plus may consider FISH verification. 6. No more than 2 chemotherapy for metastatic breast cancer. 7. At least one measurable disease according to the response evaluation criteria in solid tumor (RECIST1.1) 8. No anticancer therapy within 4 weeks 9. No neuropathy more than grade I 10. Adequate hematologic, hepatic, and renal function,No serious medical history of heart, lung, liver and kidney 11. Provision of written informed consent prior to any study specific procedures 1. Pregnant or lactating women (female patients of childbearing potential must have a negative serum pregnancy test within 14 days of first day of drug dosing, or, if positive, a pregnancy ruled out by ultrasound) 2. Women of childbearing potential, unwilling to use adequate contraceptive protection during the course of the study 3. Treatment with an investigational product within 4 weeks before the first treatment 4. Symptomatic central nervous system metastases 5. Other active malignancies (including other hematologic malignancies) or other malignancies, except for cured nonmelanoma skin cancer or cervical intraepithelial neoplasia. 6. Patient having a history of clinically significant cardiovascular, hepatic, respiratory or renal diseases, clinically significant hematological and endocrinal abnormalities, clinically significant neurological or psychiatric conditions 7. Uncontrolled serious infection 8. Previous administration of vinorelbine 9. Patients with bad compliance</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>metastatic triple-negative breast cancer</keyword>
	<keyword>vinorebine</keyword>
	<keyword>oxaliplatin</keyword>
</DOC>